Citigroup’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
Other funds holding IBRX
Citigroup's IBRX Position: Q3 2026 in Review
Citigroup reduced its ImmunityBio (IBRX) stake by 49% in Q3 2026, selling an estimated $2.16M and leaving 280,552 shares worth $2.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2606.
Citigroup first reported a position in IBRX in Q3 2015 and has held it in 45 quarters since. The position peaked at $8.17M in Q1 2025. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.
- Citigroup held 280,552 shares of ImmunityBio worth $2.65M as of Q3 2026.
- Citigroup sold 269,724 ImmunityBio shares in Q3 2026, an estimated $2.16M.
- ImmunityBio made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #2606 holding.
- Citigroup first reported a position in ImmunityBio in Q3 2015 and has held it in 45 quarters since.
- Citigroup's ImmunityBio position peaked at $8.17M in Q1 2025.
- 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.
Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.